← Back to Search

Other

Optimal Treatment Strategies for Ulcerative Colitis (VERDICT Trial)

Phase 4
Waitlist Available
Led By Vipul Jairath, MD
Research Sponsored by Alimentiv Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 8, 16, 32, 48, 64, 80, and 96
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial will help determine the optimal treatment target for UC.

Who is the study for?
Adults with active Ulcerative Colitis (UC) confirmed by clinical, endoscopic, and histological evidence can join this trial. They must be experiencing moderate to severe symptoms and not responding to current treatments. Participants should agree not to join other investigational trials during this study, be up-to-date on colorectal cancer screenings, and willing to undergo TB and hepatitis tests. Contraception is required for sexually active participants.
What is being tested?
The trial aims to find the best treatment target for UC by comparing three groups: one targeting symptom remission without steroids; another adding endoscopic remission; the third includes histological remission as well. Patients are randomly assigned in a 2:3:5 ratio respectively.
What are the potential side effects?
Potential side effects aren't specified but may include reactions related to UC treatments such as biologics or small molecules like abdominal pain, infection risks, infusion-related reactions, headache, nausea or fatigue.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 8, 16, 32, 48, 64, 80, and 96
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, weeks 8, 16, 32, 48, 64, 80, and 96 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Difference in Time to UC-related Complication Between Treatment Target Groups 1 and 3
Secondary study objectives
Assess the effect of treatment(s) on UC-related complications
C-reactive protein
Describe the change in Geboes scores from baseline to baseline to Week 16, 32, 48 and 96/end of study (EOS)
+15 more

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Symptomatic, endoscopic and histological remissionExperimental Treatment3 Interventions
Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission plus histological remission.
Group II: Symptomatic remissionExperimental Treatment3 Interventions
Treatment target defined as achievement of corticosteroid-free symptomatic remission.
Group III: Symptomatic and endoscopic remissionExperimental Treatment3 Interventions
Treatment target defined as achievement of corticosteroid-free symptomatic remission plus endoscopic remission.

Find a Location

Who is running the clinical trial?

Alimentiv Inc.Lead Sponsor
14 Previous Clinical Trials
2,582 Total Patients Enrolled
5 Trials studying Ulcerative Colitis
134 Patients Enrolled for Ulcerative Colitis
Takeda Development Center Americas, Inc.Industry Sponsor
56 Previous Clinical Trials
10,101 Total Patients Enrolled
2 Trials studying Ulcerative Colitis
148 Patients Enrolled for Ulcerative Colitis
Vipul Jairath, MDPrincipal InvestigatorAlimentiv Inc.
2 Previous Clinical Trials
638 Total Patients Enrolled

Media Library

Treatment Algorithm A (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04259138 — Phase 4
Ulcerative Colitis Research Study Groups: Symptomatic and endoscopic remission, Symptomatic, endoscopic and histological remission, Symptomatic remission
Ulcerative Colitis Clinical Trial 2023: Treatment Algorithm A Highlights & Side Effects. Trial Name: NCT04259138 — Phase 4
Treatment Algorithm A (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04259138 — Phase 4
~147 spots leftby Mar 2026